ASTRO releases breast RT guide

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 9
Volume 19
Issue 9

ASTRO has published evidence-based guidelines to define appropriate fractionation of whole-breast irradiation.

ASTRO has published evidence-based guidelines to define appropriate fractionation of whole-breast irradiation. The guidelines state that hypofractionated whole-breast irradiation is effective for patients with early-stage breast cancer who meet certain criteria, including age 50 years and older and stage T1-2 N0 disease. Also, eligible patients will not have received chemotherapy. In addition, the radiation oncologist must be able to provide a relatively uniform delivery of the radiation dose and the ability to exclude the heart from the path of the radiation beam.

For patients who do not meet these criteria, there was not enough evidence to reach a consensus for or against the use of hypofractionated whole-breast irradiation (Int J Radiat Oncol Biol Phys online, July 15, 2010).

Related Videos
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
Related Content